Skip to content

EULAR 2023: systemic lupus erythematosus

International EULAR Current

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

Fanouriakis A, et al. Ann Rheum Dis. 2024;83:15–29
DOI 10.1136/ard-2023-224762 · Summary checked against the source: 2026-11

Read or download the original

Citations give the level of evidence and grade, as written in the guideline (e.g. 1b/A), and the journal page. For kidney involvement, the 2025 EULAR update replaces recommendations 8–10 below: see EULAR 2025: lupus nephritis.

At a glance

  1. Hydroxychloroquine for everyone unless contraindicated, at 5 mg/kg real body weight/day. [1b/A · p. 17]
  2. Glucocorticoids: taper to ≤5 mg/day prednisone and stop if possible. IV methylprednisolone pulses (125–1000 mg/day for 1–3 days) for moderate–severe disease. [2a/B · p. 17]
  3. Not controlled on HCQ, or can't get steroids down: add methotrexate, azathioprine or mycophenolate, and/or belimumab or anifrolumab. [p. 17]
  4. Organ- or life-threatening disease: IV cyclophosphamide; rituximab if refractory. [2b/C · p. 17]
  5. Treat to target: remission (clinical SLEDAI 0 on HCQ, prednisone ≤5 mg) or low disease activity. [Figure 1 · p. 22]
  6. Thrombotic APS: long-term warfarin (vitamin K antagonist) after the first arterial or unprovoked venous event. High-risk aPL without APS: low-dose aspirin. [1b/B, 2a/B · p. 17]

Overarching principles

  • A. Multidisciplinary, individualised care with patient education and shared decisions.
  • B. Assess disease activity at every visit and organ damage at least yearly with validated tools (SLEDAI-2K, BILAG; SLICC damage index).
  • C. Sun protection, no smoking (smoking reduces the effect of antimalarials and belimumab), diet, exercise and bone health.
  • D. Drug choice depends on the organs involved, severity, harms, comorbidities and patient preference.
  • E. Early diagnosis, regular screening for nephritis, treatment aiming at remission, and adherence prevent flares and damage.

Adapted from EULAR 2023 Table 1 [p. 16–17]

Recommendations

Every patient

  • Hydroxychloroquine for all, unless contraindicated. [1b/A · p. 17] Target 5 mg/kg/day, adjusted for flare risk and retinal toxicity. [2b/B · p. 17] Don't stop it in remission: stopping raises the risk of flare. [p. 22]
  • Glucocorticoids dosed by organ and severity [2b/C], reduced to ≤5 mg/day [2a/B] and withdrawn where possible.
  • Vaccinate (herpes zoster, HPV, influenza, COVID-19, pneumococcus), protect bone, kidneys and CV health, and screen for cancer. [5/D · p. 17]

Escalation

  • Second line: methotrexate [1b/B], azathioprine [2b/C] or mycophenolate [2a/B], and/or belimumab [1a/A] or anifrolumab [1a/A].
  • Organ- or life-threatening disease: IV cyclophosphamide [2b/C]; rituximab if refractory [2b/C].
  • Sustained remission: taper gradually, glucocorticoids first. [2a/B · p. 17]

Organ-specific treatment

Manifestation Treatment Grade
Skin Topical steroids or calcineurin inhibitors; antimalarials; systemic steroids if needed 2b/B; 1a/A; 4/C
Second line: methotrexate, mycophenolate, anifrolumab, belimumab 1b/B; 4/C; 1a/A; 1a/B
Neuropsychiatric, inflammatory Glucocorticoids + immunosuppressants 1b/A
Neuropsychiatric, thrombotic or aPL-related Antiplatelets or anticoagulants 2b/C
Severe immune thrombocytopenia, acute High-dose glucocorticoids (IV pulses) ± IVIG, and/or rituximab, and/or high-dose IV cyclophosphamide 4/C; 4/C; 2b/B; 4/C
Thrombocytopenia, maintenance Rituximab, azathioprine, mycophenolate or ciclosporin 2b/B; 2b/C; 2b/C; 4/C
Thrombotic APS Long-term vitamin K antagonist after the first arterial or unprovoked venous event 1b/B
High-risk aPL, no thrombosis Aspirin 75–100 mg/day 2a/B

Adapted from EULAR 2023 Table 1, recommendations 5–7 and 12 [p. 17]

Treating non-renal SLE

Mild: constitutional symptoms, mild arthritis, rash ≤9% body surface, platelets 50–100 × 10⁹/L, SLEDAI ≤6, ≤1 BILAG B.

First line HCQ ± short-course glucocorticoids
Second line Methotrexate, azathioprine or mycophenolate; belimumab or anifrolumab

Moderate: RA-like arthritis, rash 9–18%, platelets 20–50 × 10⁹/L, serositis, SLEDAI 7–12, ≥2 BILAG B.

First line HCQ + glucocorticoids, with methotrexate, azathioprine, mycophenolate or a calcineurin inhibitor; or belimumab or anifrolumab
Second line Mycophenolate, calcineurin inhibitor, belimumab, anifrolumab

Severe: major organ-threatening disease (cerebritis, myelitis, pneumonitis, mesenteric vasculitis), platelets <20 × 10⁹/L, TTP-like disease, haemophagocytic syndrome, rash >18%, SLEDAI >12, ≥1 BILAG A.

First line HCQ + glucocorticoids (IV pulses), with mycophenolate, cyclophosphamide or rituximab; belimumab or anifrolumab only for extensive skin or joint disease without major organ involvement
Second line Cyclophosphamide or rituximab

Target: remission (clinical SLEDAI 0, on HCQ, prednisone ≤5 mg/day) or low disease activity (SLEDAI ≤4, HCQ, prednisone ≤5 mg/day, stable tolerated immunosuppressants or biologics). Adapted from EULAR 2023 Figure 1 [p. 22]

Clinical pearls

  • HCQ for every lupus patient, and keep it going in remission: stopping it raises the risk of flare.
  • Anifrolumab blocks the type I interferon receptor; belimumab blocks BAFF (BLyS).
  • APS: warfarin, not a DOAC, especially with arterial events or triple positivity.
  • Remission = clinical SLEDAI 0 with prednisone ≤5 mg/day on HCQ.

Classes and levels of evidence

How EULAR SLE 2023 grades its recommendations. Adapted from EULAR SLE 2023 Table 1 (Oxford levels) [p. 17]. Hover over any class or level cited on this page to see what it means.

LoE Meaning Wording used
LoE 1a Systematic review of RCTs
LoE 1b Individual RCT
LoE 2a Systematic review of cohort studies
LoE 2b Individual cohort study, or a low-quality RCT
LoE 3a Systematic review of case-control studies
LoE 3b Individual case-control study
LoE 4 Case series, or poor-quality cohort or case-control studies
LoE 5 Expert opinion
Level Meaning
GoR A Based on consistent level 1 studies
GoR B Based on consistent level 2 or 3 studies, or extrapolated from level 1
GoR C Based on level 4 studies, or extrapolated from level 2 or 3
GoR D Based on level 5 evidence, or troublingly inconsistent or inconclusive studies

EULAR tags each recommendation with a level of evidence (LoE, 1a–5) and a grade of recommendation (GoR, A–D) from the Oxford Centre for Evidence-Based Medicine, written as "1b/A". Overarching principles carry no LoE. Each statement also has a level of agreement: the panel's mean score from 0 to 10.